Durable local control
A one-time, image-guided intratumoral administration designed to deliver a high radiation dose within the tumor, and evaluated for local control endpoints.
Combination strategy
Durable local control,
built for the era of targeted therapy
Systemic therapy
YntraDose®
Systemic therapy controls disease throughout the body. It is not designed to eliminate a locally advanced primary tumor.
YntraDose® is designed to address that gap — delivering durable local control alongside the systemic regimen, without interrupting it.
The better systemic therapy becomes,
the more local control matters
A new generation of targeted agents is entering clinical development in pancreatic cancer, including inhibitors directed at KRAS — one of the defining drivers of the disease.
As these therapies extend systemic disease control, the clinical consequences of the primary tumor do not disappear.
Local progression remains a leading source of morbidity :
- Pain
- Biliary and duodenal obstruction
- Loss of eligibility for further treatment
A patient responding well systemically can still be limited by a tumor that was never treated locally.
The opportunity
BetaGlue’s opportunity grows with the success of targeted systemic therapy, rather than in competition with it.
Compatible by design
Designed to complement,
never to substitute
Treatment standards in pancreatic cancer will continue to evolve. YntraDose® is designed to remain compatible with the systemic backbones that emerge — a local component intended to be added to a regimen, not a modality competing for the same clinical role.
For pharmaceutical partners developing systemic therapies in pancreatic cancer, durable local control represents a complementary component of the treatment pathway.
YntraDose® is an investigational radiotherapeutic. Its safety and performance are being evaluated in clinical development and have not been established.